iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Glenmark and Ichnos Launch Alliance for Breakthrough in Cancer Treatments

31 Jan 2024 , 01:37 AM

In an effort to speed up the search for novel cancer treatments drugs, Glenmark announced on Tuesday that it has formed a partnership with Ichnos Sciences, its clinical stage biotech business.

‘We are optimistic about making progress in our endeavour to create an innovative cancer medication for global use,’ stated Glenn Saldanha, the chairman and managing director of Glenmark.

Saldanha continued, ‘Plus, by optimizing the cost of development, this will also enhance shareholder value.’

Targeting solid tumours, acute myeloid leukemia, and multiple myeloma, IGI has a strong pipeline of three cutting-edge oncology medicines that are presently undergoing clinical studies. This compound has been designated by the USFDA as an orphan medication.

Furthermore, IGI has two autoimmune disease assets that are under exclusive license to top businesses.

With more than 150 scientists, the new organization will make use of its three international innovation hubs.

These include the biologics research centre in Lausanne, Switzerland; Glenmark’s small molecule research centre at Mahape near Mumbai, India; and the Ichnos headquarters in New York, US, which focuses on clinical development.

In October 2019, Glenmark separated its biotech R&D division into Ichnos, a distinct company, with the goal of focusing on innovative R&D, pursuing funding sources, and making the division self-sustaining.

For feedback and suggestions, write to us at editorial@iifl.com

Glenmark Pharmaceuticals - Wikipedia

Related Tags

  • Cancer Treatment
  • Glenmark
  • Ichnos
  • Pharma
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.